Related Experiment Video
Updated: Jun 25, 2026
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
Published on: December 7, 2014
Mutational analysis of JAK1 gene in human hepatocellular carcinoma
1Department of Pathology, Microdisection Genomic Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Unlabelled:
The Janus kinase 1 (JAK1) gene encodes a cytoplasmic tyrosine kinase that is noncovalently associated with a variety of cytokine receptors and plays a nonredundant role in cell proliferation, survival, and differentiation. The mutated forms of JAK1 often altered the activation of JAK1 and then changed the activation of JAK1/STAT pathways, and this may contribute to cancer development and progression. Thus, to investigate whether genetic mutations of JAK1 gene are associated in hepatocellular carcinoma (HCC) progression, we analyzed genetic alterations of JAK1 gene in 84 human HCCs by single-strand conformational polymorphism (SSCP) and direct sequencing. Of 24 exons of JAK1 gene, 12 exons were previously reported to have mutations, we searched genetic alteration of JAK1 in these exons. Overall, one missense mutation (1.2%) was found. In addition, 12 cases (14%) were found to have single nucleotide polymorphism (14%) in exon 14. Taken together, we found one novel missense mutation of JAK1 gene in hepatocellular carcinomas with some polymorphisms. Although the functional assessment of this novel mutant remains to be completed, JAK1 mutation may contribute to the tumor development in liver cancer.
Keywords:
JAK1 gene, hepatocellular carcinoma, mutation.
Insights
Genetic mutations in the Janus kinase 1 (JAK1) gene were investigated in hepatocellular carcinoma (HCC). A novel missense mutation was identified, suggesting a potential role for JAK1 mutations in liver cancer development.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- The Janus kinase 1 (JAK1) gene encodes a cytoplasmic tyrosine kinase crucial for cell signaling pathways.
- Mutations in JAK1 can alter JAK1/STAT pathway activation, potentially contributing to cancer.
- Hepatocellular carcinoma (HCC) is a significant global health concern.
Purpose of the Study:
- To investigate the association between genetic mutations of the JAK1 gene and hepatocellular carcinoma (HCC) progression.
- To identify genetic alterations in the JAK1 gene in human HCC samples.
Main Methods:
- Analysis of genetic alterations in 84 human HCC samples.
- Utilized single-strand conformational polymorphism (SSCP) and direct sequencing.
- Focused on 12 previously reported mutation-harboring exons of the JAK1 gene.
Main Results:
- One novel missense mutation (1.2%) in the JAK1 gene was identified.
- Single nucleotide polymorphisms (SNPs) were found in 14% of cases in exon 14.
- No mutations were found in the analyzed exons, except for the single missense mutation.
Conclusions:
- A novel missense mutation in the JAK1 gene was discovered in hepatocellular carcinoma.
- JAK1 gene mutations and polymorphisms may play a role in liver cancer development.
- Further functional studies are required to fully elucidate the impact of this novel JAK1 mutation.
